看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
% ^( N( ^( b3 _+ L5 J$ R, e+ @! a$ k1 @- ~
9 N8 F) J4 H/ U8 d7 G* R
Currently available feasibility data for possible combination strategies. % z; M/ d \8 @# ~
————————————————————————————————, `$ S! L# B- d* B8 Q
Combination Feasibility according to preliminary data ; h7 @- L$ S# p5 U0 e5 m" G
——————————————————————————————————( o y, f. e# ^# B1 G) Q5 ?1 F
Bevacizumab + sorafenib Yes, reduced dose 8 Q8 f8 D, y- O7 T7 r4 r' w: M
Bevacizumab + sunitinib† No
& M; b# p; s: N v) a% S3 JBevacizumab + temsirolimus Yes
& C( [/ E" `2 a7 O1 L3 LBevacizumab + everolimus Yes 9 p" C8 H0 S/ S6 s: L1 }. I/ \7 K& ?
Sorafenib + sunitinib ? 7 F- r0 k/ V+ G: S
Sorafenib + temsirolimus Yes, reduced dose $ R6 c3 ^7 N. { I; }
Sorafenib + everolimus Yes, reduced dose
6 T; E5 O' \& _9 L2 V% iSunitinib + temsirolimus† No . b) H. _1 H0 M, \) X
Sunitinib + everolimus ? 3 I4 K% q$ P2 o( P) q
Temsirolimus + everolimus ?
4 ?( \9 P3 f2 X. N$ @6 O/ V4 U————————————————————5 B" v- F$ i, [7 }
†Led to US FDA warning.
& N* i1 k# w4 }?: As yet unattempted combination.
# k. ~+ ?) a. q6 S: d& L# a+ w$ U# f |